title: Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic.
abstract: Clinical oncology trials are hampered by low accrual rates, with fewer than 5% of adult patients with cancer treated on study. Clinical trial enrollment was evaluated at The University of Texas MD Anderson Cancer Center's Multidisciplinary Prostate Cancer Clinic (MPCC) to assess whether a clinical trial initiative, introduced in 2006, impacted enrollment. The trial initiative included posting trial-specific information in clinic, educating patients about appropriate clinical trial options during the treatment recommendation discussion, and providing patients with trial-specific educational information. The investigators evaluated the frequency of clinical trial enrollment for men with newly diagnosed prostate cancer seen in the MPCC from 2004 to 2008. Logistic regression evaluated the impact of patient characteristics and the clinical trial initiative on trial enrollment. The median age of the 1370 men was 64 years; 32% had low-risk, 49% had intermediate-risk, and 19% had high-risk disease. Overall, 74% enrolled in at least one trial and 29% enrolled in more than one trial. Trial enrollment increased from 39% before the initiative (127/326) to 84% (880/1044) after the trial initiative. Patient enrollment increased in laboratory studies (from 25% to 80%), quality-of-life studies (from 10% to 26%), and studies evaluating investigational treatments and systemic agents (from 6% to 15%) after the trial initiative. In multivariate analysis, younger men (P<.001) and men seen after implementation of the clinical trial initiative (P<.001) were more likely to enroll in trials. Clinical trial enrollment in the MPCC was substantially higher than that seen nationally in adult patients with cancer, and enrollment rates increased after the introduction of a clinical trial initiative.
authors.affiliation: From the Departments of Genitourinary Medical Oncology, Radiation Oncology, Urology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Lydia T
authors.initials: LT
authors.lastname: Madsen
authors.affiliation: From the Departments of Genitourinary Medical Oncology, Radiation Oncology, Urology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Kuban
authors.affiliation: From the Departments of Genitourinary Medical Oncology, Radiation Oncology, Urology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Seungtaek
authors.initials: S
authors.lastname: Choi
authors.affiliation: From the Departments of Genitourinary Medical Oncology, Radiation Oncology, Urology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: John W
authors.initials: JW
authors.lastname: Davis
authors.affiliation: From the Departments of Genitourinary Medical Oncology, Radiation Oncology, Urology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Jeri
authors.initials: J
authors.lastname: Kim
authors.affiliation: From the Departments of Genitourinary Medical Oncology, Radiation Oncology, Urology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Andrew K
authors.initials: AK
authors.lastname: Lee
authors.affiliation: From the Departments of Genitourinary Medical Oncology, Radiation Oncology, Urology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Delora
authors.initials: D
authors.lastname: Domain
authors.affiliation: From the Departments of Genitourinary Medical Oncology, Radiation Oncology, Urology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Larry
authors.initials: L
authors.lastname: Levy
authors.affiliation: From the Departments of Genitourinary Medical Oncology, Radiation Oncology, Urology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Louis L
authors.initials: LL
authors.lastname: Pisters
authors.affiliation: From the Departments of Genitourinary Medical Oncology, Radiation Oncology, Urology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Curtis A
authors.initials: CA
authors.lastname: Pettaway
authors.affiliation: From the Departments of Genitourinary Medical Oncology, Radiation Oncology, Urology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: John F
authors.initials: JF
authors.lastname: Ward
authors.affiliation: From the Departments of Genitourinary Medical Oncology, Radiation Oncology, Urology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Christopher
authors.initials: C
authors.lastname: Logothetis
authors.affiliation: From the Departments of Genitourinary Medical Oncology, Radiation Oncology, Urology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Karen E
authors.initials: KE
authors.lastname: Hoffman
mesh_terms: D000368:Aged; D002986:Clinical Trials as Topic; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010353:Patient Education as Topic; D018579:Patient Selection; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011795:Surveys and Questionnaires